Jorge S. Reis-Filho, MD, PhD, FRCPath
Pathologist
Titles
Chief, Experimental Pathology Service
Clinical Expertise
Experimental Pathology; Gene Expression Profiling; Genomics; Breast Cancer
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Reis-Filho accepts the following list of insurance providers. Select your insurance provider to see more details.
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS, Transplant
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO, DSN
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO, HMO, PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO EPO
Payor Type: Commercial
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): Federal Government
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO/OAP
Payor Type: Other
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): TBD
Payor Type: Commercial
In Network Coverage Type(s): HMO/EPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, EPO
Payor Type: Commercial
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Contact and Location
- 212-639-8054 Office Phone
- Speaks English
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
See all locationsAbout Me
Education
MD, Universidade do Porto (Portugal), Universidade Federal do Parana (Curitiba, Brazil); PhD, Universidade do Minho (Braga, Portugal) and The Institute of Cancer Research (London, UK)
Residencies
Universidade Federal do Parana (Curitiba, Brazil)
Fellowships
Institute of Molecular Pathology and Immunology, University of Porto (Portugal); The Institute of Cancer Research, Royal Marsden Hospital (London, UK)
I am a surgical pathologist with experience in breast cancer gene expression profiling and genomics, and in combining traditional pathology information with data generated with high-throughput molecular techniques. The main focus of my research is on rare types of breast cancer, which together account for up to 25 percent of all invasive breast cancers. Unlike the common type of breast cancer, which comprises multiple entities with distinct biological features and clinical behaviors, tumors from each of the rare types have been shown to be relatively homogeneous at the molecular level.
Read more
With the recent development of techniques that allow us to survey the entire repertoire of mutations tumor cells harbor, we now have the opportunity to ascertain which alterations drive the growth and ability of these rare types of breast cancer to metastasize, and to define potential therapeutic targets that can be used to manage not only these rare cancers but also subsets of the common types of the disease. Understanding the anatomical and biological characteristics of tumors that govern their outcome and response to specific therapies is germane for the realization of the potentials of personalized medicine.
Our laboratory in the Human Oncology and Pathogenesis Program also focuses on the impact of intra-tumor genetic heterogeneity on the biology and clinical behavior of breast cancers, and on the development of diagnostic, prognostic, and predictive biomarkers. We are currently investigating whether circulating DNA and/or circulating tumor cells can be used to define the constellation of mutations found in primary or metastatic breast cancers and whether the genetic analyses of these biological materials would complement the analysis of the primary tumor for clinical decision-making.
Memorial Sloan Kettering Cancer Center provides an optimal environment for me to pursue these research aims, given its collegial and collaborative environment, the well-characterized institutional collections of rare tumor types, and state-of-the-art research facilities.
Over the past seven years, I have lectured at various national and international conferences, and mentored PhD and MD students. I am the recipient of the 2007 CL Oakley Lectureship by the Pathological Society of Great Britain and Ireland, the British Association for Cancer Research 2007 Translational Research Award, the 2010 Ramzi Cotran Young Investigator Award by the United States and Canadian Academy of Pathology, and the 2010 Future Leaders Prize by Cancer Research UK. I am the youngest-ever Fellow of The Royal College of Pathologists to have become a member by published works. I am the international editor of Advances in Anatomical Pathology, an associate editor of The Journal of Pathology and BMC Cancer, a member of the scientific advisory board of Science Translational Medicine, and a member of the editorial board of Laboratory Investigation and Modern Pathology.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
See all Pathology and Laboratory Medicine doctors
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Reis-Filho’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Jorge S. Reis-Filho discloses the following relationships and financial interests:
-
Belgian Volition
Provision of Services -
Goldman Sachs
Provision of Services -
Oncoclinicas do Brasil Servicos Medicos S.A.
Fiduciary Role/Position; Ownership / Equity Interests
-
Paige.AI, Inc.
Ownership / Equity Interests; Provision of Services -
Personalis, Inc.
Provision of Services -
Repare Therapeutics
Ownership / Equity Interests; Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
